Summary

Judges Scientific is a £400 million serial acquirer whose thesis rests on buying niche scientific-instrument leaders at roughly 5–6x EBIT and largely leaving them alone. Chris Waller cites roughly 20% annual returns on incremental capital over 20 years, ~9% organic EBIT growth, ~40% returns on tangible capital, and a stock that compounded around 25% annually. The targets are usually £5–10 million founder-owned businesses with strong pricing power and, occasionally, effective monopolies.
The unusually low purchase multiples appear to come from founder trust, not turnarounds or aggressive synergy extraction. Judges preserves brands and operations without integrating IT systems, while private equity and strategic buyers such as Thermo Fisher or Oxford Instruments typically consolidate operations. Founders told Waller this autonomy was “the reason they sold to Judges,” and a 25-company reference base is difficult for a new imitator to replicate.
Scale will eventually reduce acquisition returns, but Waller argues Judges remains well short of that point. Halma earned 20%+ cash-on-cash returns while below £500 million of revenue, only falling toward 10% as it grew larger; Judges is at roughly £130 million. Its central team has doubled from three to six people, portfolio companies are beginning to make bolt-ons, and Waller estimates roughly £80 million of acquisition spend over the next three years.
Geotek, Judges’ largest-ever acquisition, looks more like a volatile scheduling problem than a proven failure. Roughly one-third of Geotek’s business depended on an annual scientific expedition using a specialized vessel believed to be Japanese; the 2024 trip was delayed into early 2025, and the missing revenue fell almost entirely through profit. Geotek still contributes about 20% of group free cash flow, but Waller expects that concentration to fall toward 15% in three years and 10% in six.
The immediate earnings shock is a near-freeze in US university equipment spending, not merely the announced reduction in science funding. Judges cut EPS guidance roughly 10–22% to about £3 per share, versus a share price near £60, after college purchasing largely stopped in March. Waller assumes eventual scientific-funding cuts of 20–30%, but says spending currently reflects something closer to a 100% cut because uncertainty has stopped orders: “It can’t go lower than zero.”
Founder succession is Waller’s “biggest risk,” although David Cicurel has spent years reducing his operating role and building a deeper organization. Cicurel is 76, owns stock worth roughly 200 times his base salary, and retains the acquisition-price discipline that allowed Judges to go two years without buying anything. Waller thinks a move to chairman is more likely than a complete departure or private-equity sale.
At roughly 21x free cash flow, the stock works if acquisition-led earnings continue compounding, but there is little protection from simultaneous growth and multiple compression. Andrew Walker’s bear case is a “reverse Davis double play” toward 15x if deal flow slows; Waller assumes no multiple expansion and argues comparable serial acquirers already command mid-20s to 30x multiples. He nevertheless calls the 5% three-year EPS incentive hurdle too low and says Judges should retain cash rather than pay dividends while 20% reinvestment opportunities remain.

Deep dive

1. Judges buys obscure scientific leaders with unusually strong economics

Waller describes Judges as a UK-listed, roughly £400 million market-cap serial acquirer of niche scientific-instrument companies. Its products include vacuum chambers, ultra-low-temperature cooling systems, and equipment that analyzes soils and rocks; individual systems range from thousands of pounds to as much as £1 million.
The targets are usually founder-owned private companies approaching a succession or liquidity event. They tend to lead narrow technical categories, sometimes with almost no competition, producing high pricing power, roughly 40% returns on tangible capital, and about 9% historical organic EBIT growth.
Over 20 years, Judges completed 25 acquisitions and generated roughly 20% annual returns on incremental capital; the shares returned around 25% annually. Sales are globally diversified despite a largely UK acquisition base: approximately one-third each from the US, Europe, and the rest of the world.

2. Founder trust explains the 5–6x EBIT acquisition price

Walker’s central pushback: why would rational sellers accept an average price near 5x EBIT—around 6x on a weighted basis—especially when Judges can add leverage and earn roughly 20% returns? A preference for continuity might justify a discount, but the economics still look “such a good deal” for the buyer.
Waller’s answer is that strategic buyers such as Oxford Instruments and Thermo Fisher usually integrate targets to extract obvious synergies. Even SDI, previously a close hands-off analogue, hired a CEO emphasizing joint selling and shared exhibitions—the conventional playbook that can alienate founders who care deeply about what happens after a sale.
Judges’ advantage is a 20-year reputation that cannot be copied by announcing the same policy. Prospective sellers independently checked with people they knew who could vouch for Judges and heard that it “really can trust these people”; approximately one-third of its deals may have no competing bidder.
Deal certainty reinforces that trust. Judges does not retrade, arrives with financing, and is sometimes the runner-up whose offer survives after a higher bid collapses. Walker contrasted that record with increasingly crowded search-fund outreach and highlighted the striking claim that Judges’ purchase multiple has not increased over two decades.

3. Hands-off ownership still changes the businesses where it matters

Post-acquisition autonomy is unusually literal: Judges does not merge brands, centralize operations, or even integrate IT systems. Several founders told Waller they barely noticed a difference in everyday operations, preserving the culture and technical identity that made them reluctant to sell elsewhere.
The intervention begins with information. Small companies often lack disciplined KPIs, so Judges requires monthly reporting; simply forcing attention onto financial performance can improve decisions without imposing a centralized operating model.
Founder succession is the less visible source of value. Judges manages the transition when an owner retires immediately or after several years, avoiding the value leakage that often follows a small company’s founder departure. Waller argues the portfolio’s ~9% organic growth may understate this contribution because the relevant counterfactual could have been much lower growth.
Guidance concentrates on pricing and commercially directed R&D. Judges encourages technically differentiated companies to use pricing power they had neglected and asks that research pursue a commercial outcome, “not a science project”—combining scientific expertise with a “very business focused, very returns focused” owner.

4. The runway is substantial, although diminishing returns will come

Walker’s scaling problem is mathematical: doing 1.3 small acquisitions annually mattered far more when Judges itself was smaller. Maintaining the same accretion now requires more deals or larger targets, where pricing and competition from established life-science buyers could become tougher.
Waller would rather increase the number of small deals than move materially upmarket. Judges has expanded its central team from three people—the CEO, CFO, and COO—to six, while some subsidiaries are beginning to make their own acquisitions; adjacent scientific categories and selective non-UK deals offer further, still-early avenues.
Halma supplies Waller’s strongest precedent. Its five-year cash-on-cash returns on acquisitions, CapEx, and working capital remained above 20% while revenue was below £500 million, then declined toward just over 10% as scale increased. Judges currently has only about £130 million of revenue, suggesting the bend in its return curve is not imminent.
Waller estimates Judges could deploy approximately £80 million over the next three years using free cash flow and some debt. Those targets would remain small private businesses; he concedes scientific instruments may ultimately encounter a lower ceiling than less specialized industrial roll-ups, but “there will be a point” is different from being there now.

5. Geotek’s earnings miss tests whether large deals travel well

Geotek was by far Judges’ largest acquisition—Waller puts the price at roughly £80 million, while Walker cited more than £100 million including an earnout he thought unlikely to be paid—and now contributes around 20% of free cash flow. Alongside the roughly £8 million purchases Scientifica and Armfield, its stumble encouraged investors to conclude that Judges’ model deteriorates when deal size rises.
Waller disputes a simple size rule: GDS Instruments worked well, TIER Coatings appears well suited, and seven earlier acquisitions have grown to the present scale of Scientifica and Armfield. An £8 million company is still too small to represent a structural boundary.
Geotek analyzes soil and rock samples for drilling and mining through multi-sensor, non-destructive techniques, allowing customers to reuse the sample. About one-third of revenue comes from equipping an annual ocean-floor expedition on a vessel believed to be Japanese; Waller believes only around four vessels worldwide can perform that type of expedition.
The 2024 expedition was delayed, not cancelled, and occurred in early 2025. With no expedition revenue in 2024, the loss dropped almost entirely into profit and drove negative group revenue growth and lower profitability; the first-half reversal supports Waller’s view that two years of data are insufficient to call Geotek a failed acquisition.

6. US research uncertainty has temporarily driven spending toward zero

Judges cut EPS guidance by roughly 10–22% to around £3 per share, with the stock near £60. The US supplies about one-third of revenue, and Waller estimates perhaps half of that ultimately reaches colleges—making university research spending meaningful without representing most of the company.
Since March, purchasing of new university equipment has “come to a complete halt.” Proposed reductions vary by institution from roughly 20% to 50%, including a cited 40% NIH cut, while already-awarded grants have also been frozen amid the administration’s broader confrontations with universities.
Waller admits the size of the warning surprised him because management had issued guidance in March and historically operated conservatively. His explanation is that uncertainty is more damaging than the announced cuts: even institutions outside the immediate disputes cannot know whether grants will arrive or whether they will be targeted next.
His assumption is an eventual 20–30% reduction in scientific funding, not a full recovery. Yet current ordering behaves like a 100% cut; settlements such as those cited at Columbia and Brown reduce uncertainty, so movement from “minus 100” to minus 50 or 30 could produce double-digit growth off the depressed base after the second-half and early-next-year comparisons pass.

7. Succession and valuation determine whether quality becomes a good investment

Waller calls the 76-year-old Cicurel’s succession the “biggest risk.” Cicurel has already spent much of a decade retreating from operations to focus on acquisitions, while the COO manages subsidiaries and a broader team handles sourcing and technical work; what remains hardest to reproduce is his willingness to reject overpriced deals.
Waller thinks Cicurel eventually becoming chairman is more likely than his retiring fully within three to five years. A private-equity sale appears unlikely because it would damage Judges’ anti-PE reputation and because “this company is his baby”; Waller identifies Tim Prestige as the likely internal successor.
At roughly 21x free cash flow after a near-50% decline from the peak, Waller’s thesis is straightforward: reinvesting earnings at 20% returns can generate similar earnings growth, and an unchanged multiple lets shareholders earn that growth. Walker’s counterpoint is equally clean—slower acquisitions plus a fall toward 15x could create a painful “reverse Davis double play.”
Capital allocation is not flawless. Waller agrees that a 5% three-year EPS incentive hurdle—down from 10%, partly after the UK tax rate rose from 19% to 25%—“should be higher,” though options help align newer managers. He also opposes the dividend: paying out cash below the return available from 20% reinvestment opportunities is inferior, even if UK income-fund culture and management’s personal income needs explain it.

Episode 149 - July 25, 2025 Index Ventures Partner, Martin Mignot: Figma, Scale, Wiz: Inside Index’s Decacorn Factory